SCHEMBL3577187

SCHEMBL3577187

CCOC(=O)c1c(-c2cc(O)c(O)c([N+](=O)[O-])c2)coc1-c1c(Br)nc(C)c(Cl)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 1/20 0.42
MAPT P10636 5/20 0.37
L3MBTL1 Q9Y468 2/20 0.33
MAOA P21397 2/20 0.33
MAOB P27338 1/20 0.33
ALDH1A1 P00352 4/20 0.33
GAA P10253 4/20 0.33
MAPK1 P28482 2/20 0.33
HTT P42858 1/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
LMNA P02545 2/20 0.32
HPGD P15428 2/20 0.32
PABPC1 P11940 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
PRNP P04156 1/20 0.32
AR P10275 1/20 0.32
KDM4E B2RXH2 1/20 0.31
NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27764534 0.89 COMT (0.45) COMTMAOAMAOBMEN1KMT2A
SCHEMBL1447471 0.85 COMT (0.49) COMTMAPTL3MBTL1ALDH1A1GAA
SCHEMBL3591295 0.83 MAPT (0.39) COMTMAPTL3MBTL1MAOAMAOB
SCHEMBL3586259 0.83 MAPT (0.40) COMTMAPTMAOAMAOBAR
SCHEMBL3588241 0.82 MAPT (0.40) COMTMAPTMAOAMAOBALDH1A1
SCHEMBL3592544 0.81 MAPT (0.39) COMTMAPTMAOAMAOBALDH1A1
SCHEMBL1446980 0.80 MAPT (0.39) COMTMAPTALDH1A1GAAMAPK1
SCHEMBL3588701 0.79 MAPT (0.37) COMTMAPTL3MBTL1ALDH1A1GAA
SCHEMBL3585249 0.78 MAPT (0.38) COMTMAPTL3MBTL1MAOAMAOB
SCHEMBL1447027 0.78 COMT (0.42) COMTMAPTALDH1A1GAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9446012-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-09-20 US disclosed
US-20140024682-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2014-01-23 US disclosed
US-8536203-B2 Pharmaceutical compounds BIAL-PORTELA & CA, S.A. (PT) 2013-09-17 US disclosed
EP-2617713-A1 New Pharmaceutical Compounds BIAL - Portela & Ca., S.A. (PT) 2013-07-24 EP disclosed
US-20100168113-A1 Pharmaceutical Compounds BIAL-PORTELA & CA., S.A. (PT) 2010-07-01 US disclosed
EP-2027091-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - Portela & Ca., S.A. (PT) 2009-02-25 EP disclosed
WO-2007117165-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168113-A1 Pharmaceutical Compounds PMP22, CNR2, OPRL1 COMT 10/4885MAPT 310/4885L3MBTL1 4603/4885
US-20140024682-A1 PHARMACEUTICAL COMPOUNDS PMP22, CNR2, OPRL1 COMT 10/4885MAPT 310/4885L3MBTL1 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.